Why the study?
Cisplatin use is limited by dose-dependent nephrotoxicity causing acute kidney injury in up to 45% of patients, and current preventive strategies provide questionable outcomes.
Does N-acetylcysteine prevent cisplatin-induced acute kidney injury in cancer patients receiving cisplatin-based chemotherapy?
Design
Narrative review of preclinical and clinical studies
Authors
Loading...
NAC remains promising for cisplatin-AKI prevention; leaves open confirmation in large randomized trials.
Does N-acetylcysteine prevent cisplatin-induced acute kidney injury in cancer patients receiving cisplatin-based chemotherapy?
N-acetylcysteine shows promise in preclinical models for preventing cisplatin-induced AKI, but clinical evidence remains inconsistent and requires further standardized trials.
Prabu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: